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Placental Abnormalities
Alexander L. Juusela
Abstract
A detailed discussion of normal placental development and physiology is 
beyond the scope of this chapter and is discussed in other chapters. Instead, this 
chapter will focus on an overview of congenital placental abnormalities and the 
obstetrical complications that can arise. The goal of this chapter is to delineate the 
real-world implications of placental abnormalities and provide the reader with a 
basis for understanding the other chapters that will delve into microbiology, genom-
ics, immunohistochemistry, and biochemistry of the placenta. The focus of this 
chapter will be on the developmental anomalies and this chapter will not discuss 
acquired anomalies (e.g., chorioamnionitis, amnion nodosum, metastatic tumors, 
and umbilical cord true knots). As the intention of this chapter is to focus on the 
etiopathogenesis of abnormal placentation, it is not intended to instruct the medical 
management of the described conditions, and therefore the discussions of manage-
ment will be brief. The information provided is intended for general knowledge only 
and is not intended for use in diagnosing or treating a health problem or disease 
without consultation with a qualified healthcare provider. This chapter is not a sub-
stitute for professional medical advice, or treatment for specific medical conditions.
Keywords: abnormal placentation, intrinsic placental abnormalities, 
implantation abnormalities, placental perfusion, placenta accreta, placenta previa, 
ectopic pregnancy, abruption, hematoma, vasa previa, circumvallate placenta, 
chorioangioma, amniotic band sequence, placenta membranacea, battledore 
placenta, single umbilical artery, velamentous umbilical cord, preterm labor, 
intrauterine growth retardation, intrauterine fetal demise, pregnancy complications, 
high-risk pregnancy, maternal-fetal medicine, embryology, fetal development, 
fetal intervention, obstetrical emergency, fetal surgery
1. Introduction
The placenta is a fascinating organ, unique in that it is critical for human 
development, yet becomes dispensable once extra-uterine life has begun. During 
embryogenesis, the placenta functions as the maternal-fetal interface and performs 
the roles of the lungs, liver, and kidneys for the growing gestation, as well as provid-
ing nutrition. Placental development is intriguing in the balancing act performed 
when invading the maternal endometrium to permit growth of the blastocyst, 
however, unlike neoplasms, its invasion and growth has set end points, beyond 
which pathologic states can develop Pictures 1–6.
The term placentation is defined as the formation or arrangement of the placenta 
in the body of a woman or female animal. As discussed later in this chapter under 
the ectopic implantation discussion, the definition of placentation will be extended 
beyond implantation only in the uterus to “the body”.
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Over the last couple centuries, scientific investigation has allowed us to under-
stand the embryology, anatomy, and physiology of normal and abnormal placen-
tation on both an organ system and a molecular level. We have established and 
continue expanding our understanding of how placental abnormalities and malfunc-
tions contribute to the development of maternal, fetal, and neonatal disease, with 
Picture 1. 
Placenta previa with placenta accreta.
Picture 2. 
Increased endometrial invasion by placental vasculature suspicious for placenta accreta.
3Placental Abnormalities
DOI: http://dx.doi.org/10.5772/intechopen.81579
current investigations examining the correlations between in utero conditions on 
future disease development during childhood and adulthood. Placental organogene-
sis, development, function, and malfunction remain fields of vast potential research 
Picture 3. 
Placental separation.
Picture 4. 
Velamentous cord insertion.
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that are covered in depth in other chapters in this book. The goal of this chapter is 
to delineate the real-world implications of placental abnormalities and provide the 
reader with a basis for understanding the other chapters that delve into microbiology, 
genomics, immunohistochemistry, and biochemistry of the placenta Table 1.
Picture 5. 
Placenta previa with placenta percreta invading the bladder.
Picture 6. 
Placenta previa with measured Cervical Canal.
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2. Part 1: intrinsic placental abnormalities
A. Amniotic band syndrome (sequence)—This congenital structural defect can lead 
to both minor and major malformations via entanglement of fetal structures 
in constricting rings. The malformations formed depend on the structure(s) 
entrapped in the band(s), and can range from minor constriction mediated 
limb abnormalities, amputation of extremities, complex body wall defects, 
craniofacial defects, and even gross defects non-compatible with life [1, 2]. The 
presumed etiopathogenesis leading to the clinical presentation of ABS is that 
mesodermal bands from the chorionic side of the amnion separate during early 
gestation and become attached to or entrap the embryo or germ disc [2–5]. 
Then, as the fetus grows, either via tethering bands or mechanical constric-
tion, malformations develop. There is variance in the definition and debate 
regarding the associated sequences, complexes, and syndromes. When an 
abnormal band is noted on prenatal ultrasound, the differential diagnosis must 
include uterine synechiae, a residual gestational sac, and uterine septa. Once 
these differential diagnoses are ruled out, further investigation must be taken 
to identify other fetal or placental abnormalities. To date, there are no known 
biochemical markers or genes to definitively diagnose the syndrome, however, 
there is an association with chromosomal abnormalities, and therefore the 
work-up often includes amniocentesis for karyotype as well as single nucleotide 
polymorphism (SNP) microarray [6–12]. As the presentation and complica-
tions are diverse, management depends on individual cases and ranges from 
expectant management with intervention in the neonatal/pediatric period, 
to fetoscopic band transection (fetal surgery), and even termination of preg-
nancy. The wide range of potential malformations has led to the varied ter-
minology frequently found in the literature, which includes but is not limited 
to: amniotic band syndrome, amniotic band sequence, amniotic deformity, 
adhesion mutilation (ADAM) sequence, amniotic band disruption complex, 
limb body wall complex, body wall complex with limb defects [3–5, 11, 13–18]. 
The confusion upon review of literature regarding the subject is immediately 
evident when reviewing the nomenclature. Further investigation is needed to 
determine if the ABS is a spectrum of one pathologic process or rather a collec-
tion of differing pathologic processes which result in similar outcomes.
Table 1. 
Placenta previa and placenta accreta by number of cesarean deliveries.
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B. Bipartite placenta (placenta duplex)—condition in which the placenta develops 
into two nearly symmetrical lobes with the umbilical cord insertion insert-
ing between the two lobes. The insertion can either connect with a chorionic 
bridge or into the membranes (see velamentous insertion). A rare condition, 
placentas with more than two equivalently sized lobes are termed multilobate. 
When a placenta is comprised of two or more unequally sized lobes, the 
smaller lobe(s) (or succinturiate lobe) can develop in the membranes, distal to 
the primary larger lobe, with connecting vessels running through the mem-
branes in a similar fashion to velamentous insertion. The second lobe can some-
times be located quite distant from the main lobe. Placentas with succinturiate 
lobes are not correlated with adverse fetal effects; it is at the time of labor and 
delivery that they are subject to the complications. If the succinturiate lobe 
or connecting vessels are covering the internal cervical os, the risk or vessel 
avulsion, marginal placental separation, and hemorrhage exist—equivalent to 
vasa previa and placenta previa. As the succinturiate lobe is often implanted 
in the membranes, it remains at risk for avulsion and becoming retained at the 
time of placental removal. This can lead to uterine atony, postpartum hemor-
rhage, and endometritis.
C. Chorioangioma—a benign tumor of the placenta, found in approximately 1% 
of all pregnancies, which develops from abnormal proliferation of primitive 
chorionic vessels [19]. Chorioangiomas are typically small masses without clini-
cal consequences, however, large chorioangiomas, typically lesions larger than 
4 cm, can cause hydramnios, arteriovenous (AV) shunting, and fetal red blood 
cell (RBC) sequestration. AV shunting and RBC sequestration can lead to fetal 
anemia, non-immune hydrops fetalis, fetal cardiomyopathy, intrauterine fetal 
growth restriction (IUGR), and even fetal demise [19–22]. Chorioangiomas are 
diagnosed via ultrasonography as well circumscribed solid or complex masses 
located on the fetal side of the placenta with turbulent hypervascular flow on 
Doppler-flow imaging. Management depends on the size of the mass, evidence 
of hydramnios, and evidence of fetal compromise, with management ranging 
from amnioreduction, percutaneous intrauterine transfusion, and embolization 
or laser coagulation of feeding vessels [20–22].
D. Circummarginate placenta—a rare embryologic abnormality in which hemor-
rhage and fibrin deposition separate the placenta and amniochorion. This condi-
tion is more common in multigravidas and has no known clinical significance. 
In comparison to circumvallate placenta, there is no firm ridge at the edge of 
the placenta and the margin is thin and flat. It typically is an incidental finding 
during prenatal ultrasound.
E. Circumvallate placentation—a rare embryologic abnormality in which the 
chorionic plate is unusually smaller than the basal plate, causing the amniotic 
membranes to insert medial to the placental edge. On examination, there 
is a characteristic white ring around the surface of the placental disk that is 
comprised of a double layer of amnion and chorion with fibrin and necrotic 
villi. It is predisposed to abnormal separation and commonly presents with 2nd 
trimester vaginal bleeding, being diagnosed via ultrasound or after delivery 
[23]. Pregnancy complications are common and include oligohydramnios, small 
for gestational age (SGA) neonates, abruption, and intrauterine fetal demise 
(IUFD) [24–26]. Management depends on the individual cases and subsequent 
maternal and/or fetal complications.
F. Four-vessel umbilical cord—During embryogenesis the umbilicus develops 
initially with two arteries and two veins. During the 1st trimester one umbilical 
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vein atrophies and the normal human placenta develops with one large umbili-
cal vein and two smaller umbilical arteries. Four-vessel umbilical cords are 
rare phenomena in which both umbilical veins and both arteries remain. This 
condition is associated with congenital anomalies, and when found should 
prompt further investigation; however, when it is an isolated finding the clinical 
prognosis is improved [27–29].
G. Marginal (battledore) umbilical cord insertion—This condition is called bat-
tledore placentation secondary to the shape of the placenta and cord. In this 
condition, the cord inserts at the edge of the placenta and gives it the appear-
ance of the racquet used in the precursor game to badminton. Marginal umbili-
cal cord insertions are present in approximately 6.3% of singleton gestations 
and 10.9% in twin gestations, especially in monochorionic twin gestations [30]. 
This condition rarely causes complications in singleton gestations prior to the 
3rd stage of labor, during which, the marginal cord insertion can be avulsed 
during placental delivery [31]. In monochorionic twin gestations, a marginal 
cord insertion may lead to unequal sharing of the placental mass and therefore 
lead to discordant fetal weight [32].
H. Placenta membranacea—in this rare condition, the chorionic sac is nearly or 
completely covered by placental villi. The placenta is thin, yet deeply implanted 
in the endometrium, which places it at risk for forming placenta accreta and 
previa, with the subsequent sequellae of the aforementioned conditions. Aside 
from the risks associated with placenta previa and accreta, placenta membrana-
cea is also at risk for recurrent antepartum bleeding, intra-uterine growth retar-
dation (IUGR), miscarriage, preterm labor, intrauterine fetal demise (IUFD), 
retained placenta after delivery, and postpartum hemorrhage [33–35].
I. Single umbilical artery (SUA)—SUA is an umbilical cord anomaly in which only 
one umbilical artery develops, and is the most common congenital umbilical 
cord anomaly. There are currently three proposed mechanisms of action leading 
to SUA. The first is primary agenesis of one of the umbilical arteries. The second 
is secondary atresia or atrophy of one artery in a normal three-vessel umbilical 
cord. The third is persistence of the embryologic single allantoic artery of the 
body stalk. When a SUA is identified on fetal ultrasonography, further work-up 
(detailed fetal ultrasonography, fetal echocardiography, and amniocentesis 
for karyotype) are warranted, as there is an associated high incidence of major 
chromosomal and congenital anomalies, as well as abnormalities of the renal 
and cardiac structures [36–41]. SUA is associated with intrauterine growth 
retardation (IUGR), preterm labor (PTL), small-for-gestational-dates (SGA) 
neonates, and the aforementioned structural anomalies. Twin gestations are 
affected in approximately 4–11%, without a difference in incidence between 
monochorionic and dichorionic twins [42]. When isolated SUA (iSUA) is identi-
fied, the fetus usually has normal chromosomes, and routine neonatal examina-
tion and care is indicated [43].
J. Succinturiate placental lobe(s)—see Bipartite placenta for discussion.
K. Vasa previa—an uncommon condition occurring in an estimated 0.60 per 1000 
pregnancies, in which, like to velamentous umbilical cord, the vessels pass within 
the membranes and cross over the internal cervical os [44]. In fact, vasa previa 
is often identified in conjunction with placenta previa, a velamentous cord, 
succinturiate lobes, and in the setting of in vitro fertilization (IVF). These vessels 
are also at risk of compression when fetal parts become engaged with the cervix. 
Equivalent to velamentous insertion, vasa previa is at risk of vessel avulsion 
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during membrane rupture and cervical dilation. Upon vessel avulsion, the fetus 
can precipitously exsanguinate, therefore, prenatal diagnosis is paramount in 
preventing potentially catastrophic peripartum complications [45]. The diag-
nostic modality of choice is transvaginal ultrasound with Doppler flow [46–48]. 
When diagnosed in the antepartum period, the preferred method of birth is 
planned cesarean delivery prior to the onset of labor or rupture of membranes.
L. Velamentous insertion of the umbilical cord—a potentially catastrophic umbilical cord 
anomaly in which the umbilical vessels separate in the membranes before the cord 
reaches the chorionic plate. The vessels are not covered by Wharton’s jelly and can 
therefore be easily compressed, lacerate, and rupture, leading to fetal hemorrhage 
[46]. The vessels are at greatest risk with rupturing of membranes as the vessels can 
tear. A common presenting sign is increased vaginal bleeding at the time of sponta-
neous rupture of membranes (SROM) or artificial rupture of membranes (AROM) 
[49]. Pregnancies complicated by velamentous insertion of the umbilical cord are 
associated with increased risk of PPROM, preterm labor, abruption, peripartum 
non-reassuring fetal heart tracing (NRFHT), cord avulsion requiring manual 
removal of the placenta, cesarean delivery, and fetal/neonatal death [31, 46, 49, 50]. 
When diagnosed in the antepartum period, management depends on whether or 
not the velamentous cord insertion is associated with vasa previa. When it is associ-
ated with vasa previa, the preferred method of birth is planned cesarean delivery 
prior to the onset of labor or rupture of membranes. In the absence of vasa previa, 
there is currently no evidence that cesarean delivery or induction of labor improve 
outcomes. As the vessels lack the Wharton’s Jelly found in normal umbilical cords, 
the vessels are prone to compression and avulsion, therefore laboring patients 
should have continuous fetal heart rate monitoring to allow prompt diagnosis of 
fetal distress. Additionally, there is an increased risk of cord avulsion when traction 
is applied to the umbilical cord in the third stage of labor.
3. Part 2: implantation abnormalities
A. Abnormal implantation
a. Ectopic implantation (ectopic pregnancy) occurs when the blastocyst implants in a 
site other than the uterine endometrium and is estimated at between 0.5 and 1.5% 
of all 1st trimester pregnancies in the United States [51, 52]. Ectopic implantation 
is most common in the fallopian tube (approximately 96% of ectopic pregnancies) 
[53], but it can occur in the uterine cornua, ovary, cervix, and even parasitically 
implanting into the intraabdominal organs and vessels [54–58]. Unlike the uterus, 
structures like the fallopian tube, cervix, cesarean scar, and ovary cannot accom-
modate a growing fetus, are prone to acute rupture, and the resulting hemorrhage 
can be life threatening. The current era in medicine, with diagnostic modalities 
such as ultrasound and Beta-HCG hormone blood and urine level testing, diagnos-
ing ectopic pregnancy rapidly has led to decreased morbidity and mortality. In 
the United States, the mortality rate from ectopic pregnancy has decreased since 
the 1980s, with ectopic pregnancy comprising 3% of all cause pregnancy-related 
deaths in a 2017 study [59, 60]. Risk factors for ectopic pregnancy include history of 
sexually transmitted or other pelvic infection (such as chlamydia, gonorrhea, pelvic 
inflammatory disease and tubo-ovarian abscess), prior ectopic pregnancy, tubal 
surgery, tobacco smoking, pelvic adhesions (e.g., secondary to endometriosis, sal-
pingitis, pelvic abscess, appendicitis), assisted reproductive technology, congenital 
fallopian tube abnormalities, diethylstilbestrol exposure, and Salpingitis isthmica 
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nodosa [61–63]. Patient presentation and outcomes depend on the pregnancy loca-
tion and range from pregnancy failure with reabsorption, to spontaneous abortion, 
to continued growth leading to surrounding structure rupture and hemorrhage. 
Management depends on a multitude of factors including the site of implantation, 
size of the gestational sac or fetus, beta-human chorionic gonadotropin (Beta-
HCG) hormone level, and the patient’s presenting signs and symptoms and range 
from expectant management, to intragestational or systemic methotrexate (MTX), 
to surgical intervention.
b. Placenta previa is the term when placental implantation is either adjacent to or 
covering the internal cervical os. The prevalence varies per region, however, has 
been estimated between approximately 4 and 5.2 per 1000 pregnancies, with the 
incidence of marginal placenta previas decreasing as gestational age increases 
(see discussion below for further details) [64, 65]. Further distinction is made 
between complete coverage of the internal cervical os or complete placenta 
previa versus when the leading edge of the placenta is implanted within less than 
2 cm from the internal cervical os or marginal placenta previa. The severity of 
complications varies widely based on the location of the placenta in relation to 
the cervical os, as well as the degree of placental separation. The location of the 
placenta over or at the margin of the internal cervical os leads to a predisposition 
for hemorrhage if cervical dilation occurs as any cervical dilation will expose 
placental blood vessels, leading to a range from concealed bleeding (i.e., no 
observed vaginal bleeding) to frank exsanguination. Complications during 
labor arise from both the placental separation and the structural blockage of 
fetal expulsion from the uterus by a complete previa. Depending on the placen-
tal implantation site, as the uterus grows throughout the gestation, marginal 
placenta previas, when followed by serial ultrasound examination have a docu-
mented tendency to become progressively distanced away from the internal 
cervical os. However, placenta previa remains at risk of interface separation and 
subsequent hemorrhage when contractions and/or cervical dilation occur at any 
time during the pregnancy. The etiopathogenesis of placenta previa remains 
elucidated, and the two current hypotheses are: 1. Lack of a suitable implantation 
site in the uterine fundus or corpus. Secondary to uterine trauma from previous 
surgery (e.g., cesarean deliveries, myomectomies, dilation & curettage) and/or 
multiple pregnancies, the sites of normal implantation develop areas of subop-
timally vascularized uterine decidua, which predispose to implantation of the 
trophoblast in the lower uterine segments [64]. 2. Large placental surface area, 
secondary to conditions such as multiple gestations and placenta membranacea, 
increases the probability of the placenta implanting or extending over the inter-
nal cervical os. Known major risk factors include: 1. Previous placenta previa, 
which has a recurrence in 4–8% of future pregnancies [64, 66, 67]. 2. Previous 
Cesarean deliveries, with a dose–response pattern in the risk of placenta previa, 
the risk increasing with the number of cesarean deliveries previously performed 
[68, 69]. 3. Multiple gestations—in a retrospective cohort study that included 
67,895 pregnancies, 2.1% of singleton and 2.5% of twin gestations had previa 
diagnosed. A subgroup analysis demonstrated that dichorionic twin gestations 
were at an increased risk for ultrasonography-diagnosed previa when compared 
with monochorionic or single gestations [70]. Minor risk factors include: 1. 
Increasing maternal age. 2. Increasing parity. 3. Previous non-cesarean delivery 
surgeries (uterine evacuation, myomectomy, infertility procedures). 4. Drug 
usage (tobacco smoking and cocaine usage). 5. Non-white race. 6. Male fetus. 
Management of placenta previa depends on if it is a complete or marginal previa, 
if there is a suspected concomitant placenta accreta, and then individualized 
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based on multiple factors: the estimated gestational age (EGA), the distance 
of the placental edge from the internal cervical os, any evidence of abruption, 
maternal vaginal bleeding, hemodynamic instability, or evidence of fetal distress. 
Therefore obstetricians must base management on their assessment of individual 
cases. An actively bleeding placenta previa is a potential obstetrical emergency, 
and should be handled as if having the potential for rapid hemorrhage and 
requirement for massive transfusion of blood products and crystalloid. Upon the 
onset of labor, if both the mother and fetus are stable, and the placenta is at least 
2 cm from the internal cervical os, the patient can safely undergo labor.
c. Placenta accreta spectrum (PAS)—a collection of conditions of abnormal placen-
tation caused by trophoblastic invasion into the myometrial tissue beyond the 
normal boundary established by the Nitabuch fibrinoid layer. The PAS includes 
the diagnoses of placenta accreta, increta and percreta, with the definitions 
differing solely based on the depth of invasion of the placenta into the uterus 
and even beyond the uterus into adjacent structures and organs. Whereas, in 
normal placentation, placental villi attach to the decidual basalis, microscopic 
analysis of PAS has demonstrated partial or complete absence of the decidual 
layer such that the placental villi attach and/or interdigitate with myometrial 
fibers [71–75]. Mechanical disruption of the endometrial tissue from cesarean 
deliveries, myomectomies, uterine ablation, dilation and curettage, or endo-
metritis is the current leading hypothesized etiopathogenesis of PAS [71–79]. 
Investigation is currently underway to identify other factors such as increased 
growth expression and angiogenesis that may contribute this pathologic process 
[75, 76, 80]. Physiologically, separation between placental cotyledons and the 
uterus occurs at the decidual layer, which functions as a cleavage line. In the 
absence of a decidual layer, separation between the placental cotyledons and 
the uterine spiral arteries does not occur, and the uterus continues to perfuse 
the cotyledons, which, in turn, leads to hemorrhage [77]. The current estimated 
incidence of PAS is 3.0 per 1000 pregnancies [81]. Secondary to the rise in 
frequency of operative procedures (specifically cesarean deliveries, with an 
estimated incidence increasing from 12.5% in 1982 to 32.2% in 2014 [78, 81]), 
there was a concomitant estimated increase in PAS of 0.8 per 1000 deliveries 
during the 1980s to the current estimate of 3.0 per 1000 pregnancies [78, 81–86]. 
Undiagnosed PAS can lead to massive intrapartum and postpartum hemor-
rhage, consumptive coagulopathy, disseminated intravascular coagulopathy, 
hypovolemic shock, and maternal mortality [71, 79, 87, 88]. The importance 
of antepartum placental analysis has been well established, and the individual 
practitioner must have a high index of suspicion at the time of delivery [89]. 
US and magnetic resonance imaging (MRI) are the diagnostic modalities most 
frequently used [90–93]. Identification of placental invasion of the myometrium 
can be made with US, with a positive predictive value (PPV) of 68%, a nega-
tive predictive value (NPV) of 98%, and a sensitivity of 89.5% [90]; with MRI, 
the sensitivity is 88%, specificity is 100%, PPV is 100%, and NPV is 82% [91]. 
Establishing a suspected diagnosis of PAS before delivery allows for a scheduled 
delivery and pre-operative planning with a multidisciplinary team based on 
the severity of the PAS. This can include consultation with a Maternal-Fetal 
Medicine specialists, gynecologic-oncologists, general surgeons, urologists, 
vascular surgeons, anesthesiologists, neonatologists, intensive care specialists, 
interventional radiologists, blood bank personnel, and nursing staff. There cur-
rently is inconclusive evidence for improved outcomes with pre-delivery place-
ment of ureteral stents or internal iliac artery occlusive devices. Management 
of PAS varies as widely as the degree of abnormal placentation. Case by case 
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management depends on whether or not it was identified before delivery, 
estimated gestational age (EGA), maternal factors (co-morbidities, previous 
surgery, status of labor), the size of the morbidly adherent placenta, the hem-
orrhage encountered, structures invaded by the placenta, adhesions, parity, 
presence of placenta previa, and other individualized factors. No randomized 
controlled trials (RCT) exist to guide management; therefore management 
varies between institutions and practitioners. The definitive treatment for PAS 
is cesarean-hysterectomy; however, experimental modalities aimed at uterine 
conservation have included leaving the placenta en situ followed by hypogastric 
artery ligation, uterine artery embolization, compression sutures, intrauterine 
balloon tamponade, and adjuvant methotrexate [94]. It should be noted that 
these experimental methods remain at risk for hemorrhage and delayed hys-
terectomy. It is the opinion of both the American College of Obstetricians and 
Gynecologists (Committee Opinion No. 529) as well as this author, that cases 
should be individualized, but “the recommended management of suspected pla-
centa accreta is planned preterm cesarean hysterectomy with the placenta left in 
situ.” [95] If the practitioner believes that adequate care cannot be administered, 
then transfer of care to a tertiary care center, specifically a center of excellence 
for PAS, is recommended.
d. Cervical ectopic pregnancy is a rare phenomenon, estimated at <1% of all ectopic 
pregnancies [57], while cervical placenta accreta is an even rarer condition. In con-
trast to the endometrium, the cervix does not contain a decidual layer; therefore, it 
is hypothesized that pathogenesis of cervical accretas is attributable to direct dam-
age from cervical instrumentation during in vitro fertilization, intrauterine device 
placement, dilation and curettage, cesarean delivery, and previous cervical and/or 
uterine surgery [96, 97]. While diagnosis of a cervical ectopic pregnancy is made 
via ultrasound, cervical placenta accreta is a pathologic diagnosis made after surgi-
cal procedures such as trachelectomy and hysterectomy. Therefore, management 
is that of a cervical ectopic pregnancy. Ultrasound has allowed for early diagnosis 
and attempts at preservation of reproductive capacity via intragestational potas-
sium chloride or methotrexate (MTX), local or systemic MTX, and/or uterine 
and hypogastric artery embolization [57, 96, 97]. However, when conservative 
measures fail in the acute scenario, the conventional gold standard remains total 
abdominal hysterectomy (TAH) [98].
B. Abnormal cytotrophoblastic invasion
a. Implantation of the blastocyst into the endometrium occurs between days 6 and 
7 after fertilization and is a highly regulated process that occurs in three phases: 
1. Apposition, or initial contact of the blastocyst with the endometrium; 2. 
Adhesion, or adhesion between the blastocyst and decidua, and; 3. Invasion, or 
continued penetration into and invasion of the decidua by the syncytiotropho-
blast and cytotrophoblasts, down to the inner third of the myometrium, followed 
by union with the uterine vasculature. Studies are currently underway to identify 
the exact pathways and mechanisms by which the blastocyst, like a neoplasm, 
invades the decidua, inner third of the myometrium, and stimulates local angio-
genesis to promote its own growth [99, 100]. Unlocking this complex process has 
enormous potential for the fields of oncology and reproductive endocrinology 
[101]. Investigation into the three phases of implantation have identified numer-
ous growth factors [e.g., vascular endothelial growth factor (VEGF), placental 
growth factor (PlGF), transforming growth factor-B1 (TGF-B1)], angiogenic fac-
tors, adhesion molecules, cytokines, interleukins, receptors, transcription factors, 
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and associated pathways [102–105]. For example, adhesion of the blastocyst to 
the endometrium depends on hormonally mediated Integrins, one of the four 
classes of cell receptors termed cellular adhesion molecules (CAMs) [106–108]. 
The mechanisms of impaired trophoblast migration are also currently being 
elucidated, and are associated with local placental hypoxia and abnormal placen-
tal growth factors, including placental growth factor (PlGF), hypoxia inducible 
factor (HIF), tyrosine kinase 1 (sFlt1), and reactive oxygen species [109–111]. 
Defective implantation and placentation clinically leads to recurrent spontane-
ous abortion, PPROM, IUGR, and preterm labor [112]. Inadequate or absence of 
secondary invasion of the endovascular trophoblast into the maternal spiral arter-
ies of the myometrial layers during weeks 15 to 22 of gestation is associated with 
maternal chronic hypertension (CHTN), preeclampsia, and diabetes [112, 113].
4. Part 3: processes affecting placental perfusion
A. Abnormal placental separation
a. The author acknowledges that there are various medical conditions and mecha-
nisms of action (such as trauma and hypertension) that can lead to abnormal 
placental separation, however, this topic is included in this chapter as current 
investigation is underway correlating genetics and characteristics of certain 
placentas to a predisposition for abnormal placental separation. The pathways 
and cascades that interact to prevent or promote separation and rupture of 
membranes include cytokines, transcription factors, thrombin, matrix metal-
loproteinases (MMP), prostaglandins, hormones, collagen, proteoglycans, and 
fetal fibronectin (FFN) [114–116].
b. Chorionic hematoma—a hematoma (collection of blood) between the chorion 
and the uterine wall. It occurs in an estimated 3.1% of all pregnancies and typi-
cally presents with first trimester vaginal bleeding, and is associated with spon-
taneous abortion when occurring in the first trimester [117]. Sonographically, 
hematomas appear as hypoechoic crescents with location depending on the type. 
Chorionic hematomas may mimic a thickened placenta because the hematoma 
is often isoechoic to the placenta; however, on color Doppler ultrasound there is 
the absence of internal blood flow. Three types exist:
i. Subchorionic hematoma—the partial detachment of the chorionic membranes 
from the endometrium due to mass effect by a hematoma. It is the most 
common form.
ii. Subamniotic (preplacental) hematoma—a rare form of hematoma that is 
contained within the amnion and chorion.
iii. Retroplacental hematomas—complete or partial detachment of the placenta 
from the uterine wall with a hematoma confined behind the placenta. When 
the Large hematomas can decrease trans-placental perfusion and lead to 
intrauterine growth retardation (IUGR) and oligohydramnios [118].
c. Placental abruption—Abnormal placental separation, termed abruption placen-
tae or placental abruption, is defined as the complete or partial separation of a 
normally implanted placenta from the uterine wall after 20 weeks of gestation, 
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but before delivery of the fetus. This condition affects an estimated 1 in every 
100–120 pregnancies and typically presents after 20 week of gestation; however, 
the gestational age-specific incidences depend on the underlying etiopathogenesis 
of individual cases [44, 119–121]. Placental abruption is a clinical diagnosis, and 
even with prompt diagnosis, the maternal and fetal morbidity and mortality 
can be devastating. The presentation varies from the classic scenario of post-
mechanical event (such as trauma) acute-onset painful life-threatening obstetrical 
hemorrhage with associated fetal distress noted on external fetal monitoring to 
incidentally identify painless concealed focal retroplacental hematomas with 
intraplacental anechoic areas to chronic painless vaginal bleeding [122–124]. It 
should be noted that ultrasound has a low sensitivity for diagnosing abruption, 
and therefore diagnosis should be based on clinical suspicion. Known risk factors 
include trauma, hypertensive disorders, preterm premature rupture of membranes 
(PPROM), subchorionic hematomas, and cocaine [123, 125, 126]. Management 
is individualized to the degree and severity of individual cases, ranging from 
emergent cesarean delivery for acute complete abruptions to serial surveillance 
and expectant management for contained retroplacental hematomas. While man-
agement of acute abruptions is part of the standard training for obstetricians, the 
individualized management of chronic and/or partial abruptions without evidence 
of fetal compromise or maternal instability is a less defined arena which must 
take account maternal factors (such as medical co-morbidities, hemoglobin and 
hematocrit level, blood type, evidence of coagulopathy, Bishop score, and patient 
reliability for close surveillance) as well as fetal considerations (such as gestational 
age, viability, fetal presentation, complications, estimated fetal weight, chorionic-
ity, practitioners experience). It is a scenario that often leads to consultation with 
Maternal-Fetal Medicine specialists for assistance and guidance. The mechanical 
separation at the maternal-fetal interface can decrease the placental perfusion 
in a fashion similar to placental infarcts and acute atherosis of the spiral arteries 
(please see the relevant sections of this chapter) and can lead to fetal acidemia, 
intrauterine fetal growth restriction (IUGR), small for gestational age (SGA) neo-
nates, chronic abruption-oligohydramnios sequence, and preeclampsia [127–129]. 
Abruptions with large volume hemorrhage can lead to cardiovascular compro-
mise, disseminated intravascular coagulation (DIC), and both fetal and maternal 
mortality. Patients with a history of one previous placental abruption are at 3–15% 
risk of future abruption, and women with a history of two previous abruptions 
are between 20 and 25% risk of repeat abruption [44, 130–133]. Research focused 
on preventing placental and maternal interface infarcts is currently active with 
small randomized controlled trials (RCTs) demonstrating a protective effect with 
anticoagulants administered in a subcuticular manner [134].
5. Conclusions
The placenta is an indispensable, yet temporary, organ of the developing human 
that we are rapidly improving our knowledge of via scientific investigation. Clinical 
correlates of placental abnormalities and malfunction are a common occurrence at 
prenatal testing centers and on the labor and delivery wards throughout the world. 
Placental abnormalities can lead to adverse fetal outcomes such as SGA/IUGR, dis-
cordant growth in twins, preterm birth, IUFD as well as maternal adverse outcomes 
such as hemorrhage requiring blood transfusion, surgery for retained products of 
conception, hysterectomy, and even mortality. When diagnosed in the antepartum 
or peripartum period, practitioners must take into account minimizing adverse 
consequences to both the fetus/neonate as well as the mother. Neonatal outcomes 
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vary as widely as the placental pathology outlined in this chapter and depend both 
on the EGA at diagnosis, severity of the pathology, duration, fetal attributes, as well 
as peripartum events.
Through the course of this chapter intrinsic and extrinsic placental abnormali-
ties and their clinical correlates have been described. Hopefully, this chapter 
provided you with an overview of the complex processes of abnormal placentation 
in relation to real-world outcomes, and will allow you to better understand the 
following chapters in this book.
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Future investigation
As medical practitioners, our current prenatal toolkit for treating placental 
malfunctions is limited, with the main tool being increased fetal surveillance, and 
when things go awry, the definitive intervention is delivery of the fetus. Until more 
is known regarding placental pathology and we develop methods for preventing, 
modifying, treating, or possibly even reversing the pathology, then expedited, and 
often preterm, delivery with its associated sequellae remains our principal method 
of therapy. Scientific investigation carries on at a fevered pace, with new findings 
piecing together the complex biological nature of this fascinating organ. It is this 
author’s hope that during his lifetime, new insights into the placenta on molecular, 
genetic, physiologic, anatomic, and clinical levels will lead to fetal interventions 
which thereby decrease the iatrogenic preterm birth rate, and will permit affected 
pregnancies to progress closer to term in their natural environment.
Appendices and nomenclature
ADAM amniotic deformity adhesion mutilation sequence
AROM artificial rupture of membranes
CAM cellular adhesion molecule
CHTN chronic hypertension
DIC disseminated intravascular coagulation
EFW estimated fetal weight
EGA estimated gestational age
FFN fetal fibronectin
HIF hypoxia inducible factor
IUFD intrauterine fetal demise
IUGR intrauterine growth retardation
IVF in vitro fertilization
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MMP matrix metalloproteinase
MTX methotrexate
NPV negative predictive value
NRFHT non-reassuring fetal heart tracing
PAS placenta accreta sequence
PlGF placental growth factor
PPROM preterm premature rupture of membranes
PPV positive predictive value
PTL preterm labor
RCT randomized controlled trial
sFlt1 soluble FMS-like tyrosine kinase 1
SGA small for gestational age
SUA single umbilical artery
iSUA isolated single uterine artery
SNP single nucleotide polymorphism
SROM spontaneous rupture of membranes
TAH total abdominal hysterectomy
TGF-B1 transforming growth factor-B1
VEGF vascular endothelial growth factor
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